Rubicin20 mg/vial

Rubicin is an anthracycline cytotoxic chemotherapy medicine indicated, in combination with other anticancer drugs, for remission induction in the following settings:

• Established/FDA-approved indication: Acute non-lymphocytic leukemia (acute myeloid leukemia, AML) in adults, used in combination with cytarabine as part of remission-induction therapy.
• Established/FDA-approved indication: Acute lymphoblastic leukemia (ALL) in children and adults, used in combination with vincristine and prednisone (with or without L-asparaginase) as part of remission-induction therapy.

Rubicin is always used as part of a combination chemotherapy protocol under the direct supervision of a qualified hematologist/oncologist; it is not used as a single agent and has no approved uses outside specialist leukemia treatment.

Each mL of Daunorubicin injection contains Daunorubicin (as Daunorubicin Hydrochloride) 5 mg. It is commonly supplied as single-dose vials containing 20 mg/4 mL or 50 mg/10 mL of Daunorubicin, either as a ready-to-use sterile solution or as a sterile lyophilized powder for reconstitution. Daunorubicin is available only as an intravenous formulation; there is no oral, topical, or intramuscular dosage form.

Rubicin is a cytotoxic anthracycline antibiotic derived from Streptomyces species, chemically and pharmacologically related to doxorubicin. Rubicin is used exclusively as an intravenous chemotherapy medicine for the remission-induction treatment of acute leukemias and must be administered only by, or under the direct supervision of, physicians experienced in the use of cytotoxic chemotherapy, in a facility equipped to manage the profound bone marrow suppression it produces.

Rubicin belongs to the anthracycline class of antineoplastic (anticancer) agents, a subgroup of cytotoxic antitumor antibiotics.

Daunorubicin exerts its cytotoxic effect mainly by intercalating between DNA base pairs and by stabilizing the DNA-topoisomerase II complex, preventing re-ligation of DNA strand breaks after topoisomerase II cleaves them. This results in double- and single-strand DNA breaks, inhibition of DNA and RNA synthesis, and generation of free radicals that further contribute to cell (including cardiac) toxicity.

After intravenous administration, Daunorubicin is rapidly and widely distributed into body tissues (highest concentrations in the spleen, kidney, liver, lung and heart) but does not cross the blood-brain barrier in significant amounts. It has an initial plasma half-life of about 45 minutes and a terminal half-life of about 18.5 hours. Daunorubicin is extensively metabolized in the liver to its active metabolite, daunorubicinol, and is eliminated mainly through biliary/fecal excretion (about 40%) with a smaller portion excreted in urine (about 25%).

Rubicin must be given only by slow intravenous injection into the tubing of a rapidly flowing, freely running IV infusion of normal saline or 5% dextrose, or by short IV infusion, through a securely placed venous line. Rubicin must never be given by the intramuscular, subcutaneous, or intrathecal route. It should be administered only by healthcare professionals trained in the handling and administration of cytotoxic drugs, with immediate access to protocols for managing extravasation, anaphylaxis, and severe myelosuppression. Rubicin must not be mixed in the same syringe or infusion with other medicines, especially heparin, as this can cause precipitation.

Rubicin has clinically significant interactions with several medicines:

• Other anthracyclines (e.g., doxorubicin) or prior chest/mediastinal radiotherapy: increase the cumulative risk of irreversible cardiotoxicity when combined with Rubicin; cumulative dose limits must account for prior anthracycline or radiation exposure.
• Cyclophosphamide and other cardiotoxic chemotherapy agents: may increase the risk of cardiotoxicity when given with Rubicin.
• Other myelosuppressive drugs or radiotherapy: additive bone marrow suppression when combined with Rubicin, requiring dose adjustment and close blood-count monitoring.
• Hepatotoxic drugs (e.g., high-dose methotrexate): may impair hepatic clearance of Rubicin, increasing its toxicity.
• Live vaccines: should generally be avoided during treatment with Rubicin because of the risk of disseminated infection in an immunosuppressed patient.

Bone marrow suppression (severe neutropenia, thrombocytopenia and anemia) and cardiotoxicity are the dose-limiting adverse effects of Rubicin; other common effects include:

• Nausea and vomiting, usually mild to moderate
• Mucositis/stomatitis, typically appearing 3-7 days after a dose
• Reversible alopecia (hair loss), which occurs in most patients
• Transient red-orange discoloration of urine for 1-2 days after a dose (harmless)
• Fever, chills, or rash (uncommon)
• Severe local tissue damage (necrosis, cellulitis, phlebitis) if the injection extravasates outside the vein
• Hyperuricemia related to rapid tumor cell breakdown

See Precautions and Warnings for cardiotoxicity, and Overdose Effects for signs of excessive dosing.

Rubicin is classified in FDA Pregnancy Category D and is contraindicated in pregnancy; it is cytotoxic and has been shown to cause fetal harm (including fetal abnormalities and growth impairment) in animal studies, and no adequate, well-controlled studies exist in pregnant women. Women of childbearing potential should use effective contraception during, and for a period after, treatment with Rubicin, and should avoid becoming pregnant. If a patient becomes pregnant while receiving Rubicin, she must be informed of the potential risk to the fetus.

It is not known whether Rubicin is excreted in human breast milk; because of the potential for serious adverse reactions in a nursing infant, breastfeeding should be discontinued before starting treatment with Rubicin and should not resume without a physician's advice.

Rubicin carries a boxed warning for the following serious risks and must only be given under the supervision of a physician experienced in cytotoxic chemotherapy, in a facility equipped to manage its complications:

• Cardiotoxicity: Cumulative-dose-dependent, potentially irreversible cardiomyopathy and congestive heart failure can occur with Rubicin, with risk rising sharply above a lifetime cumulative dose of 550 mg/m² (400 mg/m² if the chest was previously irradiated) in adults, or lower thresholds in children. Baseline and periodic cardiac function (ejection fraction/ECG) monitoring is required throughout and after treatment with Rubicin, and strict adherence to cumulative dose limits is essential.
• Severe myelosuppression: Profound suppression of white cells, platelets and red cells is expected with Rubicin as part of leukemia induction and requires intensive supportive care, infection precautions, and frequent blood count monitoring.
• Extravasation: Rubicin must be given via a securely placed, freely flowing intravenous line; extravasation can cause severe, difficult-to-heal local tissue necrosis and requires an immediate extravasation-management protocol.
• Tumor lysis syndrome: Patients with a high tumor burden are at risk when starting Rubicin; appropriate prophylaxis (hydration, urate-lowering therapy) and monitoring are needed.
• Radiation recall: Rubicin can reactivate skin reactions in areas previously irradiated.
• Secondary malignancy: Rare cases of secondary leukemia have been reported after treatment with topoisomerase II inhibitors such as Rubicin, particularly when combined with other antineoplastic agents or radiotherapy.
• Not for outpatient self-administration: Rubicin requires dosing individualization and administration by a specialized hematology/oncology team in an appropriate monitored inpatient or day-care oncology setting.

Overdose with Rubicin can cause severe, potentially life-threatening bone marrow suppression, severe mucositis/gastrointestinal toxicity, and acute cardiotoxicity (which may present within 24 hours or be delayed for weeks). There is no specific antidote for Rubicin overdose. Any suspected overdose requires immediate medical attention in a hospital setting, with intensive supportive care (transfusions, growth factors, antibiotics, cardiac monitoring) as clinically indicated; the patient or caregiver should contact the treating oncology team or emergency services immediately rather than attempting any home treatment.

Store unopened Rubicin vials refrigerated at 2°C-8°C (36°F-46°F), protected from light, and keep out of the reach of children. Once diluted for infusion, Rubicin solution is generally stable at room temperature (15°C-30°C) for up to 24 hours; unused reconstituted or diluted solution should be discarded, as it contains no preservative. Rubicin should be handled as a hazardous cytotoxic drug, following institutional guidelines for safe handling and disposal.

Renal impairment: Dose reduction of Rubicin (approximately 50%) is recommended when serum creatinine exceeds 3 mg/dL.

Hepatic impairment: Dose reduction of Rubicin is recommended based on serum bilirubin (about 75% of the normal dose for bilirubin 1.2-3 mg/dL; about 50% of the normal dose for bilirubin above 3 mg/dL).

Elderly patients: Adults 60 years and older typically receive a lower starting dose of Rubicin (see Dosage and Administration) because of increased susceptibility to cardiotoxicity and myelosuppression, and age-related decline in renal function.

Pediatric patients: Rubicin is approved for use in children with acute lymphoblastic leukemia as part of combination therapy; children, especially infants, may be more susceptible to cardiotoxicity at lower cumulative doses, and long-term cardiac follow-up is recommended.

The duration and number of cycles of Rubicin therapy are determined individually by the treating hematologist/oncologist according to the specific induction/consolidation protocol, the patient's response (bone marrow recovery, remission status), and tolerance of toxicity. Rubicin is typically given on 2-3 specific days within each treatment cycle, with subsequent cycles spaced to allow bone marrow recovery; treatment is stopped once the lifetime cumulative cardiotoxic dose limit is approached or if unacceptable toxicity occurs.

Where Rubicin is supplied as a sterile lyophilized powder, it should be reconstituted using sterile Water for Injection, USP, as directed on the product label, to give a solution containing approximately 5 mg/mL of Rubicin, and should be further diluted only in normal saline or 5% dextrose immediately before administration. Ready-to-use liquid formulations of Rubicin (5 mg/mL) do not require reconstitution but should still be diluted/administered as directed. Reconstitution and handling of Rubicin must be performed by trained personnel using cytotoxic-safe handling precautions.

Anthracycline; Antineoplastic/cytotoxic antibiotic; Topoisomerase II inhibitor.

Daunorubicin acts by intercalating into DNA and inhibiting topoisomerase II, thereby blocking DNA replication and RNA/protein synthesis and generating free radicals, which together lead to cell death, particularly in rapidly dividing leukemic cells.

D

Rubicin is approved for use in pediatric patients with acute lymphoblastic leukemia as part of combination induction chemotherapy, typically dosed at 25 mg/m² IV weekly with vincristine and prednisone; in infants and children under 2 years of age (or with a body surface area under about 0.6 m²), dosing is calculated by body weight (approximately 1 mg/kg) instead of body surface area. Children may be more sensitive than adults to the cardiotoxic effects of Rubicin, so lower cumulative dose thresholds apply and long-term cardiac monitoring after treatment is recommended.